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Oxazolone Colitis, a Th2 Colitis Model
Resembling Ulcerative Colitis,
Is Mediated by IL-13-Producing NK-T Cells
Th1 cytokines do not (Boirivant et al., 1998; Mizoguchi
et al., 1999).
One such Th2 model is oxazolone colitis, a recently
described colitis induced by the intrarectal administra-
tion of the haptenating agent oxazolone in an ethanol
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vehicle. In this model, the initial toxic effects of theNational Institute of Allergy
inducing agent leads to a flooding of the lamina propriaand Infectious Diseases
with oxazolone and oxazolone-modified bacterial anti-National Institutes of Health
gens and thus the induction of an immune responseBethesda, Maryland 20892
that leads to further inflammation. The latter is driven2 Gastroenterology Division
by the production of Th2 cytokines since the inflamma-Brigham and Women’s Hospital
tion is characterized by increased IL-4 and IL-5 secre-Harvard Medical School
tion, and the inflammation can be ameliorated by theBoston, Massachusetts 02115
administration of anti-IL-4 monoclonal antibodies (Boiri-3 Ter Meulen Fund
vant et al., 1998).Royal Netherland Academy of Arts and Sciences
The mechanisms by which luminal antigens stimulateThe Netherlands
an inflammatory immune response in the mucosa in
oxazolone colitis and, by extension, in human ulcerative
colitis, has until now been unclear. One possibility isSummary
that the inflammation is mediated by typical MHC class
II-reactive CD4 T cells that have been shown to playOxazolone colitis (OC) is an experimental colitis that
a major role in Th1 colitides. Another and, at first glance,has a histologic resemblance to human ulcerative coli-
more unlikely possibility is that the inflammation is medi-tis. Here we show that IL-13 production is a significant
ated by NK-T cells, i.e., a normally minor T cell popula-pathologic factor in OC since its neutralization by IL-
tion that bears both T cell and NK cell markers and13R2-Fc administration prevents colitis. We further
expresses an invariant T cell receptor- chainshow that OC is mediated by NK-T cells since it can
(V14J281 in mice; V24J18 in humans) and a re-be induced neither in mice depleted of NK-T cells nor
stricted repertoire of V chains (Lantz and Bendelac,in mice that cannot present antigen to NK-T cells and
1994). Additional characteristics of NK-T cells are thatmice lacking an NK-T cell-associated TCR. Finally, we
they are either CD4or CD4 or CD8 cells and that theyshow that NK-T cells are the source of the IL-13, since
recognize antigens that are presented by CD1 (CD1d inthey produce IL-13 upon stimulation by -galactosyl-
humans), which is a highly conserved MHC class I-likeceramide, an NK-T cell-specific antigen. These data
molecule (Balk et al., 1989) expressed on dendritic cells,thus describe a cellular mechanism underlying an ex-
macrophages, B cells (Blumberg et al., 1991; Roark etperimental colitis that may explain the pathogenesis
al., 1998), thymic epithelium (Bendelac, 1995), and gas-of ulcerative colitis.
trointestinal epithelial cells (Bleicher et al., 1990; Blum-
berg et al., 1991). While the natural antigens that areIntroduction
presented by CD1 in vivo are not known, NK-T cells can
be stimulated in vitro and in vivo by glycolipids thatThe human inflammatory bowel diseases (IBD), Crohn’s
bind to CD1, such as the prototype or model NK-T cell
disease (CD), and ulcerative colitis (UC) are believed to
glycolipid antigen-galactosylceramide (GalCer) (Gump-
be due to an abnormal mucosal T cell responsive to
erz et al., 2000; Spada et al., 1998; Saubermann et al.,
bacterial antigens contained within the gut lumen (Sar- 2000). Finally, activation of NK-T cells via CD1-pre-
tor, 1995). In CD, the responding T cells exhibit a Th1 sented antigen induces rapid NK-T cell release of Th1
phenotype and thus produce large amounts of inter- and Th2 cytokines, and then apoptosis followed by
feron- (IFN-) and tumor necrosis factor (TNF-); in expansion with continuous antigen exposure (Chen and
addition, IL-12 secretion, the driving force of Th1 differ- Paul, 1997; Eberl and MacDonald, 1998; Hayakawa et
entiation, is increased (Parronchi et al., 1997). In UC, al., 1992; Yoshimoto and Paul, 1994).
the responding T cell is less well defined. In this case, We report here that oxazolone colitis is in fact medi-
whereas Th1 cytokine production is normal or de- ated by NK-T cells and that these T cells are capable
creased and some Th2 cytokine production (IL-5 and IL- of producing large amounts of Th2 cytokines when stim-
10) is increased, the production of the signature cytokine ulated by anti-CD3/anti-CD28 or in a CD1-restricted
associated with the Th2 response, IL-4, is not increased fashion by GalCer. Initially, this consists of IL-4 secre-
(Fuss et al., 1996). Despite this discrepancy, there is a tion, but the latter is rapidly superceded by IL-13 secre-
reason to believe that UC is a Th2-mediated disease; tion. The IL-13 response appears to be a key pathogenic
several murine models of mucosal inflammation that are component of the colitis as IL-13 neutralization by IL-
clearly due to excess IL-4 secretion resemble UC on a 13R2-Fc administration prevents its development.
histopathologic level, whereas the many models due to Given the resemblance of oxazolone colitis in mice to
UC in humans, these data have important implications
for the understanding and treatment of human IBD.4 Correspondence: wstrober@atlas.niaid.nih.gov
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Figure 1. Presensitization before Intrarectal
Challenge with Oxazolone Leads to a Chronic
Progressive Colitis
Weight loss (A) and mortality (B) of mice after
presensitization with vehicle (ethanol) or oxa-
zolone and intrarectal challenge with vehicle
or different doses of oxazolone. Each study
group analyzed contained  ten mice. Data
shown represent mean values obtained from
three independent experiments. Photomicro-
graph of an H/E-stained section of colon from
a control mouse presensitized and chal-
lenged intrarectally with ethanol alone at 7
days after intrarectal challenge, 5 (C) and
10 (E). Photomicrograph of an H/E-stained
section of colon from a mouse presensitized
with 3% oxazolone and challenged intrarec-
tally with 1% oxazolone at 7 days after intra-
rectal challenge, 50 (D) and 100 (F).
Results similar to mice administered vehicle (i.e., ethanol) alone.
In addition, while nonpresensitized mice administered
3% oxazolone appeared to have only a transient weightEpicutaneous Presensitization and Intrarectal
Rechallenge with Oxazolone Leads to Chronic loss, this was in reality due to early death of most of
the mice and selective survival of a minority that hadProgressive Oxazolone Colitis Associated
with Th2 Cytokine Production only mild transient disease. As shown in Figures 1C–1F,
histological examination of mouse colons at days 7–10We have shown previously that intrarectal challenge of
naive mice with 3% oxazolone elicits a Th2 response in showed that presensitized mice developed massive
bowel wall edema and dense infiltration of the superficialthe lamina propria of the colon, known as oxazolone
colitis (Boirivant et al., 1998). However, this dose is layers of the mucosa with small polynuclear granulo-
cytes; in addition, the epithelial cell layer was disruptedhighly toxic and produces an accelerated inflammation
lasting 3–4 days that leads either to rapid recovery or, by large ulcerations. This histopathological picture is
similar to that seen in human UC and suggests that aalternatively, to death of the mice. To obtain a more long-
lived, chronic inflammatory response, we presensitized similar pathological mechanism contributes to tissue
damage in both types of inflammation. Finally, as shownC57Bl/10 mice with 3% oxazolone by skin painting 5
days before rectal challenge and then administered 1% in Figure 2A, mononuclear cells isolated from the lamina
propria (LPMC), mesenteric lymph nodes (MLNC), oroxazolone intrarectally to induce colitis. As shown in
Figures 1A and 1B, presensitized mice administered 1% spleen (SPC) of mice with oxazolone colitis produced
large amounts of Th2 cytokines (IL-4, IL-5, IL-13) butoxazolone developed colitis marked by sustained
weight loss sometimes culminating in death; nonpresen- only low levels of IFN- upon stimulation with anti-CD3
and anti-CD28 antibodies in vitro. In contrast, LPMCsitized mice given this intrarectal dose had a weight loss
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IL-13 production by LPMC (as well as MLNC or SPC)
during the same time frame increased. This phenome-
non has been observed in other animal models of inflam-
mation mediated by Th2 cells (Minty et al., 1997; Urban
et al., 1998). To establish a pathogenic role for IL-13 in
oxazolone colitis, we neutralized IL-13 by in vivo admin-
istration of IL-13R2 fused to the Fc portion of human
IgG1 (IL-13R2-Fc) at the time of intrarectal oxazolone
administration. This fusion protein binds to IL-13 with
high affinity and neutralizes IL-13 bioactivity in vitro and
in vivo (Donaldson et al., 1998; Urban et al., 1998). As
shown in Figure 3, mice treated with IL-13R2-Fc were
protected from the induction of oxazolone colitis; after
an initial transient weight loss similar to that observed
with administration of ethanol alone, IL-13R2-Fc-
treated mice rapidly regained their initial body weight,
and by day 5 colonic histology was indistinguishable
from that of mice that were given ethanol alone (data
not shown).
NK1.1-Positive Cells Are Essential for the Induction
of Oxazolone Colitis
As described above, mononuclear cells isolated from
mice with oxazolone colitis produce increased amounts
of IL-13 in vitro when stimulated with anti-CD3 and anti-
CD28. However, when we purified these mononuclear
cells by a negative selection column to enrich for CD3-
positive cells (see Experimental Procedures), our ability
to stimulate IL-13 production was greatly diminished
(data not shown). Since the selection column contains
glass beads coated with anti-mouse IgG, it has the po-
tential to retain cells that express Fc-receptors (CD16
or CD32) that are coated with immunoglobulins; thus,
it seemed possible that IL-13 production by anti-CD3-
Figure 2. Cytokine Production from Lymphocytes from Mice with
stimulated LPMC in oxazolone colitis requires a Fc-Oxazolone Colitis
receptor-positive cell. In addition to mast cells and B(A) Lamina propria mononuclear cells (LPMC), hepatic mononuclear
cells, NK and NK-T cells express CD16 (Koyasu, 1994)cells (HMNC), mesenteric lymph node cells (MLNC), and splenocytes
and are capable of producing IL-13 (Terabe et al., 2000).(SPC) were isolated on day 5 after induction of oxazolone colitis
(stippled) or TNBS colitis (black) and stimulated in vitro for 48 hr To investigate whether either of the latter two cell types
with plate-bound anti-CD3 and soluble anti-CD28. Baseline values are involved in oxazolone colitis we depleted mice of
of LPMC for IL-4 and IL-13 of ethanol-treated mice were nondetect- NK1.1 cells by repeated injection of a monoclonal anti-
able. The data shown represent the mean values obtained from
NK1.1 antibody (PK136) before challenge with oxazo-three independent experiments. All cytokine values obtained with
lone (see Experimental Procedures). Such treatment de-cells from mice with oxazolone colitis were significantly different
pleted all NK and NK-T cells, as determined by DX5from cells from mice with TNBS colitis (p  0.01).
(B) LPMC were isolated on days 2, 5, or 8 after induction of oxazolone and NK1.1 staining of splenocytes (data not shown). As
colitis. LPMC were stimulated as above, and the concentrations shown in Figures 4A and 4B, we found that mice de-
of IL-4 (open bars) and IL-13 (striped bars) were measured in the pleted of these cell types did not develop weight loss
supernatants. The data show IL-4 and IL-13 values on day 8 as
or macroscopic/microscopic evidence of colonic inflam-compared to day 2 in LPMC; p 	 0.01. The data shown represent
mation and did not manifest increased Th2 cytokinethe mean values obtained from three independent experiments.
production after intrarectal administration of oxazolone
(data not shown).
In further studies to determine if this pathogenic roleisolated from C57Bl/10 mice with TNBS colitis produced
undetectable levels of IL-4 and IL-5 and only low levels for NK1.1-positive cells is specific for oxazolone colitis,
we compared NK1.1-depleted C57Bl/10 mice with un-of IL-13 upon stimulation under the same conditions.
treated C57Bl/10 mice in their susceptibility to TNBS
colitis, a Th1 model of colitis resembling human Crohn’sIL-13 Production in Oxazolone Colitis Increases
during the Course of Inflammation and Is Essential disease. As shown in Figures 4C and 4D, depletion of
NK1.1-positve cells did not significantly influence weightfor the Induction of the Colitis
In further studies of cytokine secretion in oxazolone loss or mortality of mice with TNBS colitis. On the con-
trary, there was a trend toward greater weight loss incolitis shown in Figure 2B, we found that IL-4 production
by LPMC isolated at different time points during the depleted mice. These results suggest that cells bearing
NK1.1 in the mucosa play, if anything, an inhibitory rolecourse of the colitis gradually decreased. In contrast,
Immunity
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Figure 3. Neutralization of IL-13 Prevents In-
duction of Oxazolone Colitis
(A) Weight loss and (B) survival in mice pre-
sensitized with 1% oxazolone, intrarectally
challenged with 1% oxazolone, and then
treated with IL13R2-Fc or control protein at
the time of intrarectal challenge. Each study
group analyzed contained  ten mice. The
data shown represent the mean values ob-
tained from three independent experiments.
for the induction of a Th1-associated inflammation such amination of lamina propria, whereas littermate controls
developed moderately severe disease. These resultsas that occurring in TNBS colitis, an effect previously
noted in other models of Th1-mediated intestinal inflam- thus provide strong evidence that oxazolone colitis is
mediated by T cells responding to antigens presentedmation (Saubermann et al., 2000).
by class I MHC molecules, including NK-T cells.
In further studies we focused on whether oxazoloneNK-T Cells Are Required for the Induction
of Oxazolone Colitis colitis depends on interactions specific for NK-T cells
rather than all class I-restricted cells. In one approach toWhereas the above studies show that oxazolone colitis
is mediated by NK1.1-positive cells, they do not provide this question, we determined whether oxazolone colitis
was affected by blockade of antigen presentation by theinformation on whether the latter cells are NK or NK-T
cells, as the NK1.1 antigen is present on both of these atypical MHC class I molecule, CD1, i.e., the presenting
molecule directly involved in NK-T cell activation. Thiscell types. In an initial set of studies addressing this
question, we determined if we could induce oxazolone was accomplished by administration of a monoclonal
anti-CD1 antibody that has been shown to block CD1 incolitis in2m-deficient mice, recognizing that NK-T cells
(but not NK cells) require antigen presentation by an vivo without depleting NK-T cells and without affecting
antigen presentation by MHC class II (Park et al., 1998).atypical class I MHC molecule (Zhang et al., 1996). As
shown in Figures 5A–5D, despite the fact that the back- As shown in Figure 6, administration of this antibody at
the time of intrarectal oxazolone administration pre-ground strain of the 2m mice used in these studies is
relatively resistant to the development of this form of vented the development of oxazolone colitis.
In another complementary approach to the samecolitis, the 2m-deficient mice were clearly free of colitis
following administration of oxazolone per rectum as question, we conducted studies of CD1-deficient mice
that both lack the ability to present antigens to NK-Tmeasured by weight loss, survival, and microscopic ex-
Figure 4. Depletion of NK1.1-Positive Cells
Protects Mice from Oxazolone Colitis but Not
TNBS Colitis
Weight loss (A and C) and mortality (B and
D) after induction of oxazolone colitis (A and
B) or TNBS colitis (C and D) or injection of
vehicle (ethanol). Mice were injected with
control antibody or depleted of NK1.1 cells
with anti-NK1.1 (PK136). Each study group
analyzed contained  ten mice. The data
shown represent the mean values obtained
from three independent experiments.
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Figure 5. 2m-Deficient Mice Are Resistant
to the Development of Oxazolone Colitis
2m-deficient mice (B6/SJL background) and
their wild-type littermates (B6/SJL) after in-
duction of oxazolone-colitis. Wild-type mice
but not 2m-deficient mice lost weight and
had poor survival (A and B). In addition,
whereas 2m-deficient mice did not manifest
microscopic evidence of inflammation (C),
wild-type mice manifested inflammation
characterized by epithelial ulceration, inflam-
matory cell infiltration of the mucosal superfi-
cial layers, and edematous bowel wall (D). It
should be noted that the level of inflammation
developing in these wild-type mice was
milder than that observed in Bl10 wild-type
mice because the B6/SJL strain is relatively
resistant to oxazolone-colitis. Each study
group analyzed contained ten mice per
group.
cells and lack NK-T cells. As shown in Figure 6, we while NK-T cells lose their expression of NK1.1 upon
activation (Chen and Paul, 1997) another NK/NK-T cellshowed that intrarectal administration of oxazolone to
presensitized CD1-deficient mice does not result in the marker, Ly49C, is upregulated on activated NK-T cells.
With these limitations in mind, we observed that duringdevelopment of colitis as manifested by weight loss or
(in data not shown) by histologic changes in colonic the course of oxazolone colitis total CD3 lymphocyte
numbers isolated from mice on day 5 after inductiontissue. Despite the fact that CD1-deficient mice lack
NK-T cells, they have been shown to be fully capable of colitis undergo substantial increases in the lamina
propria (10-fold increase) and spleen (2-fold increase).of mounting certain types of Th2 responses (Smiley et
al., 1997); thus, this result cannot be attributed to an Moreover, in the lamina propria and in the spleen the
relative number of NK-T cells increases to a greaterintrinsic failure of the CD1-deficient mice to mount a
Th2 response. In parallel studies also shown in Figure extent than other cell populations. Thus, while in the
lamina propria of untreated mice, 7% (NK1.1) or 0.4%6, we showed that J281-deficient mice that lack NK-T
cells expressing the invariant TCR associated with these (Ly49C) of the CD3 T cells coexpress an NK-T cell
marker; in the lamina propria of mice with oxazolonecells are also resistant to the induction of oxazolone
colitis as manifested by weight loss or (in data not colitis, 21% of the infiltrating T cells express NK1.1 and
34% express Ly49C. Similarly, in the liver, where theshown) by histologic changes in colonic tissue. While
most CD1-restricted NK-T cells utilize this invariant TCR, highest percentage of NK-T cells can be found, NK1.1
expression on CD3 T cells increases from 9.9% to 48%there are some data that suggest the existence of NK-T
cells with other TCRs. However, even if these atypical of cells. Finally, while in the spleen of untreated mice
3.1% of CD3 cells express NK1.1, in the spleen ofNK-T cells are present in the J281-deficient mouse,
they are nevertheless insufficient to induce the inflam- mice with oxazolone colitis 5.1% express NK1.1, and
the number of Ly49C-expressing cells increases frommatory response mediating oxazolone colitis. Thus, it
appears likely that this inflammation is in fact mediated 0.6% to 28%. To summarize these findings, T cells with
surrogate markers of NK-T cell function undergo a sub-by NK-T cells expressing the invariant TCR and that the
NK-T cells are NK1.1J281CD16CD4 cells. stantial expansion in the lamina propria, the liver, and
the spleen during the course of oxazolone colitis.
NK-T Cells Undergo Expansion
during Oxazolone Colitis CD4 NK-T Cells Produce IL-13 in Response
to CD1-Restricted Antigen PresentationIn further studies we sought to determine the extent to
which the lamina propria of mice with oxazolone colitis Finally, to investigate the cytokine production of the
LPMC and SPC in response to stimulation by antigenis infiltrated with NK-T cells. However, this goal was
complicated by the fact that whereas NK1.1 is a frequent presented by CD1, we stimulated these cells with
GalCer, a synthetic glycolipid that has been found tomarker of NK-T cells, T cells with NK-T cell function have
also been identified in the NK1.1-negative population activate most invariant NK-T cells in a CD1-dependent
fashion (Kawano et al., 1997). MHC-class II-restricted T(Hameg et al., 1999). In addition, most NK-T cell markers
are dependent on the level of cellular activation. Thus, cells and NK cells are not activated by GalCer; thus,
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upon thorough histologic assessment, proved to be sim-
ilar in several respects to human UC. Skin exposure to
oxazolone has previously been shown to induce CD4 T
cell-mediated delayed hypersensitivity upon secondary
skin challenge; here we show that such exposure also
sensitizes mice to a secondary response in the gastroin-
testinal mucosa. It should be noted, however, that
whereas the reaction in the skin is mild and self-limited,
it is severe and progressive in the mucosa. This is proba-
bly due to the fact that the antigenic milieu of the colon
is far different from that in the skin and leads to the
stimulation of different effector cells and/or regulatory
cells. While the inflammation developing in the colon
in oxazolone colitis is similar to a previously reported
hapten-induced colitis, TNBS colitis (Neurath et al.,
1995), in that it is a CD4 T cell-driven response, it differs
from TNBS colitis by the fact that the CD4 T cells
produce Th2 rather than Th1 cytokines. Moreover, in-
variant NK-T cells responding to CD1-restricted anti-
gens rather than conventional T cells responding to MHC
class II-restricted antigens appear to be the major cell
type responsible for this Th2 cytokine secretion.
The pathogenic pathway leading to tissue injury in
TNBS colitis and by extension, in Crohn’s disease, can
with some confidence be attributed to production of
Th1 cytokines such as IFN- and TNF-. These effector
molecules induce tissue injury via their activation of
downstream effector cells and the resulting secretion
of proteases and proapoptotic factors. On the other
hand, the pathogenic pathway leading to tissue injury
in oxazolone colitis is less clear in that Th2 cytokines
(e.g., IL-4, IL-13, IL-10) have been shown to have a gen-Figure 6. CD1 Antigen Presentation and J281 NK-T Cells Are Es-
sential for Induction of Oxazolone Colitis erally downmodulatory effect on MHC class II expres-
sion by antigen-presenting cells and would thus tend(A) Weight loss of mice after intrarectal injection of ethanol or oxazo-
lone after i.v. injection of blocking CD1 antibodies (20H2) or control to inhibit activation of T cells (Brown and Hural, 1997;
antibody. (B) Weight loss after induction of oxazolone colitis of Fiorentino et al., 1991; Moore et al., 1993; Zurawski and
CD1/ mice, J281/ mice, and wild-type mice. Each study group de Vries, 1994); in addition, these cytokines would also
analyzed contained  ten mice. Weight loss and/or graded histo-
inhibit downstream effector cells. However, the findinglogic changes were statistically significant for both groups of knock-
that NK-T cells within lamina propria expand and areout mice versus wild-type mice (at least a p value  0.03). Both
essential for disease induction in oxazolone colitis canthe CD1/ and J281/ mice were backcrossed onto the BL/6
background (CD1/ [N10] and J281/ [N6]). help explain how a severe progressive inflammation can
evolve in spite of these inhibitory effects of Th2 cyto-
kines. One factor that comes into play as a possible
basis of NK-T cell-mediated tissue injury is that NK-Tstimulation with GalCer represents a way to assess
cells are activated by antigen in the context of CD1NK-T cell activation in unseparated cell mixtures. As
(CD1d in humans), a molecule widely expressed in theshown in Figure 7, when LPMC or SPC from mice with
colonic epithelium and dendritic cells (Blumberg et al.,oxazolone colitis were stimulated withGalCer they pro-
1991; Spada et al., 2000). It is probable that such activa-duced large amounts of Th2 cytokines, including very
tion initially involves recognition of antigens associatedhigh quantities of IL-13. In addition, CD4-positive cells
with CD1 on dendritic cells; however, as the inflamma-isolated by MACS purified from LPMC or SPC also re-
tion proceeds there is likely to be disruption of the nor-sponded to GalCer with very high IL-13 production,
mal barrier between epithelial cells and lamina propriaindicating that many of these CD4 cells in cell popula-
T cells which leads to activation of NK-T cells by antigen/tions from mice with oxazolone colitis are CD1-restricted
CD1 on intestinal epithelial cells (R.S.B., unpublishedNK-T cells.
data). More importantly, at this stage, epithelial cells
can become cytolytic targets of NK-T cells that have
Discussion been previously activated by dendritic cells. The end
result is loss of epithelial cells, the formation of epithelial
In the present study we describe an animal model of ulcers, and the intensification of inflammation due to
colitis mediated by Th2 NK-T cells producing IL-13. The entry of organisms that can now breach the epithelial
colitis was induced by intrarectal administration of a barrier. This situation is similar to that described in re-
relatively low dose of oxazolone subsequent to skin cent studies of OVA-specific CD8 T cells transferred
sensitization with oxazolone. A highly reproduceable to mice expressing ovalbumin in the intestinal epithe-
lium. In this study, the transferred cells initially expandand chronic colonic inflammation was obtained that,
Oxazolone Colitis and IL-13-Producing NK-T Cells
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Figure 7. Cytokine Production in Response
to GalCer
LPMC (upper panel), splenocytes, or spleen
CD4 cells (lower panel) were isolated on day 8
after induction of oxazolone colitis and either
stimulated or not stimulated (unstimulated)
for 48 hr with plate-bound anti-CD3 and solu-
ble anti-CD28 (CD3/CD28), untransfected
L cells (LCD1) and vehicle (GalCer Solvent),
or CD1 transfected L cells and 100 ng/ml
GalCer (LCD1 and GC). Each study group
analyzed contained  ten mice. The data
shown represent the mean values obtained
from three independent experiments. IL-13
secretion levels induced by GalCer in CD4
cells from mice without oxazolone colitis
were below the limit of detection.
and then are deleted unless the mouse is systemically gastrointestinal tract with granulocytes and that this
pathologic effect is probably mediated by induction ofimmunized with VZV-ovalbumin, in which case extensive
cytolytic destruction of the epithelium occurs along with IL-13 secretion (Fort et al., 2001). In oxazolone colitis,
IL-13 can conceivably activate epithelial cells to secretegut wall inflammation (Vezys et al., 2000). Thus, if poten-
tially cytolytic cells in the gut wall (in this case NK-T cells) mucus and fluid; in addition, this cytokine as well as IL-4
can lead to disruption of epithelial cell tight junctionsare appropriately activated, they can cause extensive
tissue injury. Finally, in recent studies of Con A-induced (Ceponis et al., 2000) which, in turn, opens the way to
invasion of bacteria. Finally, NK-T cells may indirectlyhepatitis, a model of autoimmune hepatitis also medi-
ated by NK-T cells, it was shown that tissue injury is require an IL-13 signal to proliferate, as IL-13 may also
increase CD1 antigen presentation on epithelial cells;induced by release of perforin and granzymes as well
as induction of Fas-mediated apoptosis (Kaneko et al., thus, IL-13 as such may exert a positive feedback effect
on NK-T cell-mediated tissue injury.2000). Similar cytolytic mechanisms causing lysis of epi-
thelial cells by NK-T cells are likely to exist in oxazolone Given the resemblance of oxazolone colitis to human
UC at the histopathological level, the data presentedcolitis.
A second factor that has a possible role in tissue injury here lead to the question of whether the mechanisms
resulting in oxazolone colitis also underlie the humanmediated by NK-T cells in oxazolone colitis is that NK-T
cells produce IL-13. Thus, in the studies presented here, disease. It is known that UC is not a Th1 T cell-driven
inflammation as is CD, yet it cannot readily be classifiedwe show that while IL-4 is the initial cytokine produced
in oxazolone colitis, IL-4 is rapidly superceded by IL-13 as a Th2 disease since IL-4 secretion is not increased
(Fuss et al., 1996). Our finding that a Th2 colitis resem-production and that indeed when IL-13 is neutralized,
the administration of oxazolone does not induce any bling UC can be mediated by NK-T cells producing IL-13
leads to the possibility that a similar mechanism under-histological changes or other signs of inflammation. This
strongly suggests that IL-13 acts as an effector cytokine lies the human disease. This possibility is strengthened
by the fact that both in ulcerative colitis and in estab-that mediates tissue injury in the mucosa. Precedent for
this possibility comes first from studies of animal models lished oxazolone colitis IL-4 production from T cells is
not evident. If indeed NK-T cell-producing IL-13 ac-of asthma, in which IL-13 has been shown to induce
increased mucus secretion and airway hyperrespon- counts for inflammation in UC, it could explain the fact
that inflammation in this disease involves continuoussiveness (Grunig et al., 1998; Wills-Karp et al., 1998). In
addition, it has recently been shown that infusion of IL- areas of the bowel rather than discontinuous areas as
in CD. Thus, in UC, the inflammation usually starts in the25, a newly discovered cytokine, causes epithelial cell
hyperplasia, mucus production, and infiltration of the rectum where the bacterial load is highest, and where an
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Experimental Proceduresunderlying dysregulation of the immune response might
therefore lead to the stimulation of NK-T cells by anti-
Mice and In Vivo Treatment Protocolsgen-presenting cells expressing CD1d. The IL-13 se-
Male C57Bl/10 mice were obtained from a breeding facility main-
creted by activated NK-T cells could then spread the tained by the National Cancer Institute (NCI, Bethesda, MD) and
inflammation to neighboring tissues by upregulating were housed under specific pathogen-free (SPF) conditions. Five-
to seven-week-old mice were used for all experiments. C57Bl/6-CD1d and causing injury to the epithelial cell barrier in
CD1/ mice were a generous gift from M. Exley (Spada et al., 1999);that tissue.
C57Bl/6-J281/ mice have been described previously (Cui et al.,The studies reported here revealed certain difficulties
1997) and were bred at the animal facility of Beth Israel Deaconessin identifying NK-T cells in active inflammatory lesions
Medical Center, Harvard Medical School (Boston, MA) (kindly pro-
which may impede their study in human disease states. vided by Dr. M. Exley). B2m-deficient B6/SJL and wild-type B6/SJL
We found that, whereas only a relatively small fraction of mice were purchased from Taconic Farms animal facility. Oxazolone
(4-ethoxymethylene-2-phenyl-2-oxazoline-5-one) was obtainedthe CD3 cells extracted from inflamed mucosal tissues
from Sigma-Aldrich (St. Louis, MO). In order to presensitize mice,expressed NK-T cell markers, purified CD4 cells ob-
a 2  2 cm field of the abdominal skin was shaved, and 200 
l oftained in the same way responded vigorously to
a 3% (w/v) solution of oxazolone in 100% ethanol was applied. 5
GalCer, an antigen that only activates invariant NK-T
days after presensitization mice were rechallenged intrarectally with
cells. In addition, we found that pretreatment with anti- 150 
l 1% oxazolone in 50% ethanol or only 50% ethanol (i.e.,
NK1.1 antibodies prevented oxazolone colitis, indicating vehicle) under general anesthesia with isoflurane (Baxter, Deerfield,
IL). Intrarectal injection was administered with a polyurethane umbil-that pathogenic NK-T cells must have been NK1.1-posi-
ical catheter (Sherwood, St. Louis, MO). Neutralization of IL-13 intive prior to disease induction. These discrepancies be-
vivo was performed with IL-13R2-Fc (gift of Deb Donaldsson, Wy-tween observable NK-T numbers and NK-T cell function
eth Research, Cambridge, MA). Mice received 5  200 
g of IgG2acan be explained by the observation that NK-T cells lose
(control Ig) or IL-13R2-Fc starting on the day before presensitiza-
their expression of NK1.1 after activation and that CD3 tion i.v. and then every other day i.p. Depletion of NK1.1 cells
and NK1.1 only poorly define activated NK-T cells in was achieved by injecting 250 
g anti-mouse NK1.1 monoclonal
antibodies (clone PK136) i.v. 48 hr before and after sensitization.disease states. Currently, the only conclusive method
Control mice received mouse IgG2a. FACS analysis of splenocytesfor identifying NK-T cells is staining with CD1d tetra-
from treated animals showed that NK as well as NK-T cells weremers,and indeed such staining has recently identified
completely depleted (data not shown). Antigen presentation by CD1both CD4 and CD4CD8 NK-T cell subpopulations in
molecules was blocked in vivo with anti-mouse CD1.1 (clone 20H2,
humans. In addition, in accord with the data presented gift from A. Bendelac). Mice were injected with 1 mg antibody every
here, CD1d-tetramer staining revealed that in humans 2 days, starting from the time of intrarectal oxazolone challenge.
only CD4 NK-T cells produce IL-13 (Lee et al., 2002).
Finally, it should be noted that a subset of human NK-T Histology
Mice were euthanized 5 days after induction of colitis. The colonscells express the canonical T cell receptor V24 which
were removed and segments were fixed in formalin (Fisher, Faircould also be used as a NK-T cell marker in humans.
Lawn, NJ). After paraffin embedding 5 
m sections were cut andThat this marker may indeed prove useful is supported
stained with hematoxylin/eosin (Lerner, New Haven, CT).by our finding that J281 knockout mice are resistant
to oxazolone colitis, suggesting that the V14-positive
Cell Isolation and Cytokine ProductionCD1-reactive T cells expressing the invariant TCR-
Splenocytes (SPC), mesenteric lymph node cells (MLNC), or lamina
chain associated with CD1 reactivity are involved in coli- propria cells were isolated at various time points after colitis induc-
tis induction. tion. Cells were isolated as described in detail in Current Protocols
of Immunology (Scheiffele and Fuss, 2002). In brief, LPMC wereNK-T cells that act as effector cells in oxazolone colitis
isolated after removal of epithelial cells by incubation of colon stripshave been shown to play a regulatory role in other mod-
in HBSS/2.5 mM EDTA. Mononuclear cells were released by digest-els of murine inflammation (Ishikawa et al., 2000; Kumar
ing the tissue in ISCOVES media supplemented with 10% FCS,et al., 2000; Sonoda et al., 1999; Strober et al., 1996).
200 U/ml collagenase (Roche, Indianapolis, IN), 10 
g/ml DNase 1
This may be due to their potential to downregulate Th1 (Roche), and 1 
g/ml gentamicin (BioWhittaker, Walkersville, MD).
inflammation via the production of Th2 cytokines. These Finally, leukocytes were separated from epithelial cells by centrifu-
gation in a Percoll gradient (Amersham, Piscataway, NJ) of 33%findings suggest that a possible treatment of human
and 66%. MLN cells and splenocytes were isolated by grinding thedisease mediated by Th1 cytokines is the stimulation of
tissue in a petri dish and filtering the cell suspension through a 40NK-T cells. Indeed, such an approach has already been

m mesh. Spleen cells were treated with ACK lysis buffer to lysedeveloped to treat murine experimental allergic enceph-
red blood cells (Biosource, Camarillo, CA). Initially, CD3 cells were
alitis and has proved to be effective (Miyamoto et al., isolated with mouse T cell selection columns (R&D, Minneapolis,
2001). It should be noted, however, that this mode of MN) according to the manufacturer’s instructions. Purified CD4 cells
were positively selected with CD4-beads and MACS minicolumnstreatment might also be very harmful since, as shown
(Miltenyi, Auburn, CA) according to the manufacturer’s instructions.here, Th2-cytokine producing NK-T cells can cause coli-
Cells were cultured in RPMI 1640 supplemented with 10% FCS,tis and since others have shown that these cells can
20 mM HEPES, 5% NCTC, 2 mM Glutamine, 50 
g/ml penicillin/
cause hepatitis (Takeda et al., 2000). streptomycin, 50 
g/ml gentamicin, 50 
M 2-mercaptoethanol, and
In summary, our data indicate that CD4 NK-T cells 50 U rhu IL-2 ml. T cells were stimulated in vitro with plate-bound
producing IL-13 induce a progressive colitis resembling anti-CD3 (10 
g/ml clone 2C11, Pharmingen, San Diego, CA) and
soluble anti-CD28 (1 
g/ml clone 37.51, Pharmingen). Stimulationhuman UC. This model of inflammation can be effectively
of T cells with GalCer was accomplished using a fibroblast cellblocked by neutralizing the IL-13, depleting NK-T cells,
line (L-929) transfected with mouse CD1 as antigen-presenting cells.or inhibiting the activation of NK-T cells through CD1.
CD1-transfected cells (LCD1) were a kind gift from Dr. W. Paul (Chen
If any of these mechanisms is involved in the pathogene- and Paul, 1997). L cells were treated for 1.5 hr with mitomycin C
sis of human UC, they might represent a possible treat- and seeded at 1  105 cells/ml. -galactosylceramide (GalCer;
Kirin, Tokyo, Japan) or vehicle was added at 100 ng/ml. Lymphocytement option for this disease.
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concentrations were generally 1  106 cells/ml. After 48 hr culture, presenting cell to inhibit cytokine production by Th1 cells. J. Immu-
nol. 146, 3444–3451.supernatants were harvested and stored at20C until further analy-
sis. IL-4 and IL-5 were measured with OptEIA ELISA sets from Phar- Fort, M.M., Cheung, J., Yen, D., Li, J., Zurawski, S.M., Lo, S., Menon,
mingen. IL-13 was measured with a Quantikine M ELISA kit from S., Clifford, T., Hunte, B., Lesley, R., et al. (2001). IL-25 induces IL-4,
R&D (Minneapolis, MN). IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity
15, 985–995.
FACS Analysis
Fuss, I.J., Neurath, M., Boirivant, M., Klein, J.S., de la Motte, C.,
Cells were stained with antibodies to CD3 (2C11), CD4 (RM4-5),
Strong, S.A., Fiocchi, C., and Strober, W. (1996). Disparate CD4
NK1.1 (PK136), Ly49C (5E6), Ly6C (AL-21), and DX5 after incubation
lamina propria (LP) lymphokine secretion profiles in inflammatory
with FcBlock (2.4G2) (all from BD Pharmingen, San Diego, CA).
bowel disease. Crohn’s disease LP cells manifest increased secre-
Surface staining was analyzed on a FACScanner (Becton-Dickinson,
tion of IFN-gamma, whereas ulcerative colitis LP cells manifest in-
Mansfield, MA). Percentage values were calculated with CellQuest
creased secretion of IL-5. J. Immunol. 157, 1261–1270.
software after gating on living lymphocytes in the scatter diagram.
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